Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Binge Eating Disorder
Interventions: Sodium Oxybate; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Colorectal Disorders
Interventions: Furosemide, Celecoxib, Gabapentin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 47
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 34 more

Conditions: Pregnancy, Labor Pain
Interventions: Routine oxytocin, Half-dose oxytocin; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Substance Use
Interventions: Hastiin Bidziil, Control condition - vehicle maintenance; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Chinle, Arizona • Fort Defiance, Arizona

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 13
States / cities: Cypress, California • Irvine, California • Los Angeles, California + 10 more

Conditions: Healthy Volunteer
Interventions: [14C]-EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ileus, Gastrointestinal Dysfunction
Interventions: Alvimopan; Drug
Lead sponsor: Scott Steele; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deglutition Disorders, Respiratory Aspiration
Interventions: Cold Liquid Barium; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 36 Weeks to 43 Weeks
Enrollment: 4,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Chronic Spontaneous Urticaria
Interventions: Ligelizumab, Omalizumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more

Conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions: Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 7
States / cities: Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more

Conditions: Obesity
Interventions: Roux-en-Y Gastric Bypass (RYGB), Sleeve Gastrectomy (SG), Very Low Calorie Diet (VLCD); Procedure · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 20 more

Conditions: Human Immunodeficiency Virus
Interventions: Maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more

Conditions: Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Lymphedema of Upper Limb, Lymphedema of the Hands, Edema, Edema Arm, Breast Cancer Lymphedema, Breast Cancer Metastatic, Breast Cancer Stage, Breast Cancer
Interventions: Perometer, SOZO device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Colorectal Cancer
Interventions: Amifostine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anterior Segment of Eye
Interventions: Lightfield Medical Vscan001 Automated Slit-lamp Camera; Device
Lead sponsor: Lightfield Medical; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Golden Valley, Minnesota

Conditions: Parkinson's Disease, Aging
Interventions: Respiratory resistive load on inhalation, Fluoroscopic swallowing evaluation; Other
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Osteoarthritis of the Knee
Interventions: FX006 10 mg, FX006 40 mg, TCA IR 40 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Cancer,, Solid Tumors, Advanced Solid Malignancies
Interventions: AZD6918, gemcitabine, pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Aurora, Colorado • Nashville, Tennessee

Conditions: Breast Cancer, Skin Reactions Secondary to Radiation Therapy
Interventions: Dakin's solution, radiation therapy, questionnaire administration, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Inotropy, Fluid Management, Cardiac Event, Perioperative Cardiac Risk, Vascular Resistance, Hemodynamic Monitoring, Hemodynamic Management, Fluid Responsiveness
Interventions: RESIPI Management Strategy, No intervention; Procedure · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
Interventions: GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio + 1 more

Search by objective public record fields.

Sodium Oxybate in the Treatment of Binge Eating Disorder

Early Diuresis Following Colorectal Surgery

Vitamin D to Improve Outcomes by Leveraging Early Treatment

Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

The Hastiin Bidziil (Strong Man) Intervention

Gammagard Liquid and rHuPH20 in PID

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Alvimopan as a Rescue Treatment of Postoperative Ileus

Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Cerebrospinal Fluid Biomarkers in Bariatric Surgery

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Screening For BCRL In Targeted Therapy For Breast Cancer

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

Feasibility Study of a Novel Automated Slit Lamp Camera (Lightfield Medical Ophthalmic Camera Model Vscan001)

Respiratory Load Magnitude Estimation in PD

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)